Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders
Neuropsychopharmacology
.
2017 May;42(6):1179-1181.
doi: 10.1038/npp.2016.193.
Epub 2016 Sep 19.
Authors
G Sanacora
1
,
H Heimer
2
,
D Hartman
3
,
S J Mathew
4
,
M Frye
5
,
C Nemeroff
6
,
R Robinson Beale
7
Affiliations
1
Yale Depression Research Program, Yale University School of Medicine, New Haven, CT, USA.
2
Cure Alliance for Mental Illness, Providence, RI, USA.
3
Ketamine Advocacy Network, Seattle, WA, USA.
4
Baylor College of Medicine, Houston, TX and Michael E. Debakey VA Medical Center, Houston, TX, USA.
5
Mayo Clinic, Rochester, MN, USA.
6
University of Miami, Miami FL, USA.
7
Blue Cross of Idaho, Boise, ID, USA.
PMID:
27640324
PMCID:
PMC5437876
DOI:
10.1038/npp.2016.193
No abstract available